Royalty Report: Drugs, Pharmaceuticals, HIV / AIDs – Collection: 26720


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Pharmaceuticals
  • HIV / AIDs

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 26720

License Grant
Licensor, government organization of Malaysia, hereby agrees to the grant of License by NIH to Licensee to make, have made, use and sell License Product in the Licensed Territory under any right, title or interest that Licensor may have related to the Licensed Product.  Licensee shall, subject to the conditions stipulated in this Agreement, have the right to grant sublicences.
License Property
CalanolideA is a non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV.
Field of Use
The rights granted apply to the field of HIV.

IPSCIO Record ID: 372475

License Grant
Licensor grants an exclusive, sub-licenseable, non-transferable license, under the Licensor IP and Licensor s interests in the Joint IP, to make, have made, use, sell, offer for sale and import Licensed Compounds and Products in the Field in the Territory.
License Property
Product means any pharmaceutical product containing one or more Licensed Compound as an active pharmaceutical ingredient.

Licensed Compound means any NNRTI, a non-nucleoside reverse transcriptase inhibitor, compound claimed in the Licensor Patent Rights, including those referenced as X-1008, X-1020. X- 1041, X-1050, X-1067, X-1068 and X-1069 and/or all continuations, divisions, reexaminations, renewals, registrations, reissues and extensions of any of the foregoing Patent Rights, both foreign and domestic, that are Controlled by Licensor during the Term, including X899 and X989 and all back-up compounds, follow-on compounds, prodrugs and metabolites of such compounds, as well as their isomers, salts, hydrates, solvates and polymorphs.

– X899 means (2-Carbamoyl-5-chloro-l H-indol-3-yl )-[3-( (E)-2-cyano-vinyl )-5-methyl-phenyl ]-phosphinic acid methyl ester, stereoisomers or salts thereof.

– X989 means (2-Carbamoyl-5-chloro-4-fluoro-lH-indol-3-yl)-[3-{(E)-2- cyano-vinyl)-5-methyl-phenyl]-phosphinic acid methyl ester, strereoisomers or salts thereof.

The patents relate to Phosphoindoles
– Phospho-indole as HIV Inhibitors
– Enantiiomerically Pure Phosphoindoles as HCV and HlV Inhibitors
– Dual Release Formulation of Phosphoindole Compound

IDX899 is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) being developed for the treatment of HIV-1. Licensor has advanced IDX899 through a Phase II proof-of-concept study in HIV-1 infected treatment-naïve patients that was completed in 2008

Field of Use
IDX899 is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) in Phase II clinical development being developed by Idenix for the treatment of HIV/AIDS.  New NNRTIs are needed to address the increasing prevalence of viral resistance and side effects associated with this drug class. To date, IDX899 has demonstrated high potency with low milligram doses, a high barrier to drug resistance, favourable risk/benefit profile, and the convenience of once-a-day administration.

IPSCIO Record ID: 25888

License Grant
We received the exclusive right to manufacture, use and sell the nucleotide compounds covered by these agreements from the Academy of Sciences of the Czech Republic, government organization.
License Property
Viread a drug for treating HIV infection. Viread is a formulation of a nucleotide analogue reverse transcriptase inhibitor, tenofovir DF, dosed as one 300 mg pill, once a day as part of combination therapy to treat HIV infection in adults.
Field of Use
This agreement pertains to the medical industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.